Clinical Trials

68 results for Prostate Cancer


CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION

  • Condition: D011471, D064129, D035683, D009360, D014408
  • Intervention: Diagnostic Test: Periodic ARV7 and miRNA evaluation
  • Study ID: NCT04188275
View Trial

Real World Evaluation of Access-driven Canadian Treatment Sequences in Progressive Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
  • Study ID: NCT04281147
View Trial

A Phase Ib/II Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: Rucaparib, Drug: Copanlisib
  • Study ID: NCT04253262
View Trial

A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)

  • Condition: Metastatic Castrate Resistant Prostate Cancer
  • Intervention: Drug: Docetaxel, Radiation: Radium 223
  • Study ID: NCT03737370
View Trial

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
  • Intervention: Drug: AMG 160
  • Study ID: NCT03792841
View Trial

18F-Fluciclovine PET CT as an Indicator of Therapeutic Response in Metastatic Prostate Carcinoma (M1PCa)

  • Condition: Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
  • Intervention: Procedure: Computed Tomography, Drug: Fluciclovine F18, Procedure: Positron Emission Tomography
  • Study ID: NCT04134208
View Trial

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: REGN5678, Drug: Cemiplimab
  • Study ID: NCT03972657
View Trial

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Re

  • Condition: Metastatic Castrate Sensitive Prostate Cancer
  • Study ID: NCT04497844
View Trial

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Prostate Cancer, Prostate Adenocarcinoma
  • Study ID: NCT04446117
View Trial

ESCALATE, A Phase III Randomized Study Comparing Enzalutamide or Darolutamide With Radium-223 vs Enzalutamide or Darolutamide With Placebo and the Effect Upon Symptomatic Skeletal Event-Free Survival for mCRPC Patients

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Study ID: NCT04237584
View Trial

A Phase Ib, Open-Label, Multicenter Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer.

  • Condition: Castration-Resistant Prostatic Cancer
  • Study ID: NCT04404140
View Trial

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTE

  • Condition: Hormone-Sensitive Prostate Cancer
  • Study ID: NCT04493853
View Trial

Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study

  • Condition: Prostate Cancer
  • Intervention: Drug: AZD1775, Drug: Savolitinib, Drug: Darolutamide
  • Study ID: NCT03385655
View Trial

Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04506567
View Trial

ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Study ID: NCT04419402
View Trial

Changes in 18F-fluciclovine Positron Emission Tomography (PET) in Patients With Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate: A Pilot Study

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Study ID: NCT04158245
View Trial

A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Study ID: NCT04647526
View Trial

A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy

  • Condition: Advanced Prostate Cancer
  • Intervention: Biological: HPN424
  • Study ID: NCT03577028
View Trial